Warning: The NCBI web site requires JavaScript to function. more...
Recent translational research: computational studies of breast cancer.
Retsky M, Demicheli R, Hrushesky W, Speer J, Swartzendruber D, Wardwell R.
Breast Cancer Res. 2005;7(1):37-40. Epub 2004 Dec 17. Review.
Related citations
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.
Williams C, Brunskill S, Altman D, Briggs A, Campbell H, Clarke M, Glanville J, Gray A, Harris A, Johnston K, Lodge M.
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. Review.
Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.
Adv Exp Med Biol. 2007;608:1-22. Review.
Review of gene-expression profiling and its clinical use in breast cancer.
Stadler ZK, Come SE.
Crit Rev Oncol Hematol. 2009 Jan;69(1):1-11. Epub 2008 Jul 9. Review.
A review and critique of modelling in prioritising and designing screening programmes.
Karnon J, Goyder E, Tappenden P, McPhie S, Towers I, Brazier J, Madan J.
Health Technol Assess. 2007 Dec;11(52):iii-iv, ix-xi, 1-145. Review.
Evaluation of the current knowledge limitations in breast cancer research: a gap analysis.
Thompson A, Brennan K, Cox A, Gee J, Harcourt D, Harris A, Harvie M, Holen I, Howell A, Nicholson R, Steel M, Streuli C.
Breast Cancer Res. 2008;10(2):R26. Epub 2008 Mar 27. Review.
Translational research and the changing face of breast cancer.
Dowsett M.
Breast Cancer Res Treat. 2004;87 Suppl 1:S1-2.
A computational model of reasoning from the clinical literature.
Rennels GD, Shortliffe EH, Stockdale FE, Miller PL.
Comput Methods Programs Biomed. 1987 Apr;24(2):139-49.
Gene expression profiling in breast cancer.
Morris SR, Carey LA.
Curr Opin Oncol. 2007 Nov;19(6):547-51. Review.
[Development of antituberculous drugs: current status and future prospects].
Tomioka H, Namba K.
Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.
Prognostic scores in brain metastases from breast cancer.
Nieder C, Marienhagen K, Astner ST, Molls M.
BMC Cancer. 2009 Apr 7;9:105.
uPA and PAI-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trial.
Annecke K, Schmitt M, Euler U, Zerm M, Paepke D, Paepke S, von Minckwitz G, Thomssen C, Harbeck N.
Adv Clin Chem. 2008;45:31-45. Review.
Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends.
Moreno-Aspitia A, Perez EA.
Clin Ther. 2009 Aug;31(8):1619-40. Review.
Recent translational research: circulating tumor cells in breast cancer patients.
Müller V, Hayes DF, Pantel K.
Breast Cancer Res. 2006;8(5):110. Review.
Improved breast cancer prognosis through the combination of clinical and genetic markers.
Sun Y, Goodison S, Li J, Liu L, Farmerie W.
Bioinformatics. 2007 Jan 1;23(1):30-7. Epub 2006 Nov 26.
INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
[No authors listed]
Drugs R D. 2007;8(3):176-87. Review.
Comparing genetically engineered mouse mammary cancer models with human breast cancer by expression profiling.
Shoushtari AN, Michalowska AM, Green JE.
Breast Dis. 2007;28:39-51. Review.
Systems biology for cancer.
Khalil IG, Hill C.
Curr Opin Oncol. 2005 Jan;17(1):44-8. Review.
Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
Drugs R D. 2007;8(5):321-34. Review.
Prognostic factors for breast cancer and their use in the clinical setting.
Kapoor A, Vogel VG.
Expert Rev Anticancer Ther. 2005 Apr;5(2):269-81. Review.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on